Latest news with #AspenPharmacare
Zawya
7 days ago
- Business
- Zawya
Aspen boosts regional expansion via HQ in Riyadh
Riyadh – Aspen Pharmacare Holdings Limited, a global speciality and branded multinational pharmaceutical company, launches a new regional headquarters (HQ) in Riyadh, according to a press release. The Saudi expansion followed a series of Middle East investments in key therapeutic areas to meet the market demands and support Aspen's growth strategy, which focuses on talent development, localization, and partnerships. Daniel Vella Friggieri, Regional CEO Europe and Middle East, Aspen Pharmacare, said: 'The large-scale changes that have occurred in Saudi Arabia's healthcare landscape offer us a tremendous opportunity. Aspen's new regional headquarters in Riyadh ensures that we can fully align with the Kingdom's healthcare delivery objectives and mutual goal setting under Vision 2030.' Wesam Nehad, Aspen Pharma RHQ General Manager, commented: 'Expanding in Saudi Arabia allows Aspen to build on our already well-established, strong capabilities across the Middle East – namely, an efficient distribution network, operational excellence, and a highly skilled team.' It is worth indicating that Aspen focuses on marketing and manufacturing a wide range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through its key business segments. It wide variety of product types includes steriles, oral solid dose, liquids, semi-solids, biologicals, and active pharmaceutical ingredients.
Trade Arabia
25-05-2025
- Business
- Trade Arabia
Aspen Pharmacare opens regional HQ in Riyadh
Aspen Pharmacare Holdings Limited, a global specialty and branded multinational pharmaceutical company, has announced the establishment of its new regional headquarters in Riyadh, the capital of the Kingdom of Saudi Arabia (KSA). Following a series of Middle East investments in key therapeutic areas aligned with both patient needs and market demands, the new regional headquarters will support Aspen's regional growth strategy which includes a focus on three key pillars, namely, talent development, localization, and partnerships. Daniel Vella Friggieri – Regional CEO Europe & Middle East, Aspen Pharmacare, said: "We are delighted to be strengthening our local presence in this crucial market. The large-scale changes that have occurred in Saudi Arabia's healthcare landscape offer us a tremendous opportunity." "Aspen's new regional headquarters in Riyadh ensures that we can fully align with the Kingdom's healthcare delivery objectives and mutual goal setting under Vision 2030," he stated. According to him, KSA has experienced a dynamic transformation with a large influx of expatriate professionals. "This country now ranks among Aspen's top five markets in the Middle East and Europe, underpinning the Group's strategy to significantly enhance its presence in this area. Aspen has also identified several Saudi-based initiatives as high-priority projects, further reinforcing the company's commitment to the Kingdom," he added. Wesam Nehad, Aspen Pharma RHQ General Manager, said: "Expanding in Saudi Arabia allows Aspen to build on our already well-established, strong capabilities across the Middle East - namely, an efficient distribution network, operational excellence, and a highly skilled team." "As we continue to grow, we are committed to expanding our reach and enhancing patient access to high quality, affordable medicine across the Kingdom and wider region," he stated. Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through its key business segments, including manufacturing and commercial pharmaceuticals comprising injectable products, prescription and OTC medicines.
Zawya
25-05-2025
- Business
- Zawya
Aspen reinforces Saudi market leadership with new Middle East region HQ in Riyadh
Riyadh, KSA – Aspen Pharmacare Holdings Limited ('Aspen'), a global specialty and branded multinational pharmaceutical company, has announced the establishment of a new regional headquarters in Riyadh, the capital of the Kingdom of Saudi Arabia (KSA). Following a series of Middle East investments in key therapeutic areas aligned with both patient needs and market demands, the new regional headquarters will support Aspen's regional growth strategy which includes a focus on three key pillars, namely, talent development, localization, and partnerships. Daniel Vella Friggieri – Regional CEO Europe & Middle East, Aspen Pharmacare, said: 'We are delighted to be strengthening our local presence in this crucial market. The large-scale changes that have occurred in Saudi Arabia's healthcare landscape offer us a tremendous opportunity. Aspen's new regional headquarters in Riyadh ensures that we can fully align with the Kingdom's healthcare delivery objectives and mutual goal setting under Vision 2030.' KSA has experienced a dynamic transformation with a large influx of expatriate professionals. This country now ranks among Aspen's top five markets in the Middle East and Europe, underpinning the Group's strategy to significantly enhance its presence in this area. Aspen has also identified several Saudi-based initiatives as high-priority projects, further reinforcing the company's commitment to the Kingdom. Wesam Nehad, Aspen Pharma RHQ General Manager, added: 'Expanding in Saudi Arabia allows Aspen to build on our already well-established, strong capabilities across the Middle East – namely, an efficient distribution network, operational excellence, and a highly skilled team. As we continue to grow, we are committed to expanding our reach and enhancing patient access to high quality, affordable medicine across the Kingdom and wider region'. Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through its key business segments, including manufacturing and commercial pharmaceuticals comprising injectable products, prescription and OTC medicines. Aspen's wide variety of product types includes steriles, oral solid dose, liquids, semi-solids, biologicals and active pharmaceutical ingredients. About Aspen Group Aspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets. We have more than 9,300 employees at 63 established offices in over some 46 countries and territories and we improve the health of patients in more than 115 countries through our high quality, affordable medicines. For more information, visit
Web Release
25-05-2025
- Business
- Web Release
ASPEN REINFORCES SAUDI MARKET LEADERSHIP WITH NEW MIDDLE EAST REGION HQ IN RIYADH
Aspen Pharmacare Holdings Limited ('Aspen'), a global specialty and branded multinational pharmaceutical company, has announced the establishment of a new regional headquarters in Riyadh, the capital of the Kingdom of Saudi Arabia (KSA). Following a series of Middle East investments in key therapeutic areas aligned with both patient needs and market demands, the new regional headquarters will support Aspen's regional growth strategy which includes a focus on three key pillars, namely, talent development, localization, and partnerships. Daniel Vella Friggieri – Regional CEO Europe & Middle East, Aspen Pharmacare, said: 'We are delighted to be strengthening our local presence in this crucial market. The large-scale changes that have occurred in Saudi Arabia's healthcare landscape offer us a tremendous opportunity. Aspen's new regional headquarters in Riyadh ensures that we can fully align with the Kingdom's healthcare delivery objectives and mutual goal setting under Vision 2030.' KSA has experienced a dynamic transformation with a large influx of expatriate professionals. This country now ranks among Aspen's top five markets in the Middle East and Europe, underpinning the Group's strategy to significantly enhance its presence in this area. Aspen has also identified several Saudi-based initiatives as high-priority projects, further reinforcing the company's commitment to the Kingdom. Wesam Nehad, Aspen Pharma RHQ General Manager, added: 'Expanding in Saudi Arabia allows Aspen to build on our already well-established, strong capabilities across the Middle East – namely, an efficient distribution network, operational excellence, and a highly skilled team. As we continue to grow, we are committed to expanding our reach and enhancing patient access to high quality, affordable medicine across the Kingdom and wider region'. Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through its key business segments, including manufacturing and commercial pharmaceuticals comprising injectable products, prescription and OTC medicines. Aspen's wide variety of product types includes steriles, oral solid dose, liquids, semi-solids, biologicals and active pharmaceutical ingredients.
The Citizen
30-04-2025
- Business
- The Citizen
JSE reaches a new high
Banking, retail and property stocks have been buoyed by expectations of a Sarb repo rate cut in May. Some stocks continue to face volatility – as was the case with Aspen Pharmacare last week when it saw a 30% share price wipeout in a single day. Picture: AdobeStock The JSE closed at a new high on Tuesday following the long weekend, with the All Share Index (Alsi) topping 91 300 points. While Africa's biggest bourse ended the day just 0.65% firmer, the new record means it is up over 8% year to date despite the volatility caused by US President Donald Trump's tariff moves. Banking, retail, and property stocks have been buoyed by expectations of a rate cut from the South African Reserve Bank (Sarb) next month, after the country's inflation rate for March came in lower than anticipated and at an almost five-year low. Gold stocks, which have been on a tear this year with record bullion prices, lost a bit of shine over the past week, but some JSE counters closed firmer on Tuesday. Ironically, the new JSE high comes as Trump's trade war has also seen the oil price slump to around the $60 a barrel mark in April – its lowest level since 2021 – which has helped cool SA inflation. While Trump has paused his proposed much higher global reciprocal tariffs on most nations for 90 days, barring China, volatility could return depending on how negotiations with different nations progress. Some stocks, like global pharmaceutical shares, continue to face volatility – as was the case with JSE-listed SA major Aspen Pharmacare last week, with its 30% share price wipeout in a single day. ALSO READ: Investing in JSE shares: What you need to know Aspen lost over R22 billion in market cap last Wednesday. It has however recovered some losses – closing Thursday 6% up, and around another 1% up on both Friday and this Tuesday. The Durban-based group's market cap plunged to around R49.9 billion last Wednesday, but had firmed to just over R54.1 billion after Tuesday's close. Current market darling Capitec jumped significantly last week, after announcing record results, briefly taking top spot as the JSE's biggest banking group by market cap. It topped the R3 500-a-share mark after releasing its results last week, and again on Tuesday, although it closed 0.91% up at R3 484.13 with a market cap of R404.5 billion. Banking giant FirstRand regained the top spot, closing even stronger on Tuesday, 2.42% up, taking its market cap to around R410.7 billion. Other banking majors Standard Bank, Nedbank and Absa closed 1.9%, 2.03%, and 1.92% firmer on Tuesday, respectively. The JSE's Financials 15 index jumped 1.61%. Source: Moneyweb/Profile Data ALSO READ: Global trade war's potential blow to Southern African Customs Union revenue Mobile giant Vodacom, together with sector junior peer (and Cell C major shareholder) Blue Label Telecoms, and financial services groups OUTsurance and Momentum, all hit 52-week highs on the JSE on Tuesday. Vodacom closed more than 2% up, OUTsurance 1.83% firmer, and Momentum jumped over 3%. There were more JSE winners than losers on the day, with small-cap property company Acsion Limited gaining the most, surging almost 20%. However, amongst the JSE Top 40 stocks, MTN and Clicks both gained over 3%. Besides the banking groups, Sanlam and Shoprite also gained – up 2.29% and 1.82 %, respectively. 'All-time highs are great, especially coming after the long weekend and considering the Vat mess, global trade wars, and concerns about our government of national unity [last week],' said Simon Brown of Just One Lap. 'Our market still powered ahead, underpinned by gold miners but banks and even industrials are coming to the party,' added Brown. ALSO READ: Weekly economic wrap: Policy reversals and lowest inflation in 5 years Psychological level The JSE first broke through the new psychological level of 90 000 points on 19 March, but plunged a few weeks later after Trump first announced his reciprocal tariffs against most of the US's trading partners. After Trump backtracked with a pause on most tariffs, many global markets recovered some losses, while others – like the JSE – are trading at record highs. In terms of major listed property stocks, Vukile Property Fund closed 1.74% up, and Growthpoint was just over 1% firmer. Vukile brushed off a major power outage on Monday that hit Spain and Portugal, a region which now makes up over 60% of its overall property portfolio. Following its latest acquisitions in Valencia (Spain) and Madeira (Portugal), the group's share price hit a more than five-year high last week. It touched R19.15 a share last Tuesday, and the group's market cap is now above R23 billion. This article was republished from Moneyweb. Read the original here.
